Background & Aims: A simultaneous decline in pro-and anticoagulant drivers in pa-
| INTRODUC TI ON
Patients with liver diseases frequently acquire substantial alterations in their haemostatic system. 1 A simultaneous decline in pro-and anticoagulant drivers results in a "rebalanced" haemostatic system. [2] [3] [4] External factors may tip the balance towards hypo-or hypercoagulability, 5 and distinct hypo- [6] [7] [8] [9] [10] and hypercoagulable [11] [12] [13] [14] features in patients with liver disease which may predispose them to bleeding or thrombotic complications.
Bleeding and thrombosis are not uncommon in patients with liver disease, in particular in those with advancing and decompensated illness. 15 However, little evidence-based treatment strategies for prevention or treatment of bleeding or thrombosis are available.
Current expert recommendations propose a very restrictive prophylactic prohaemostatic management, and a more active anticoagulant approach. 5, 16, 17 Importantly, anticoagulant therapy in patients with cirrhosis is challenging, 18 and new generation anticoagulant drugs have not been extensively studied in patients with cirrhosis, although the clinical use in these patients is increasing. 19, 20 Decompensation may tip the haemostatic balance of patients with liver disease towards a bleeding phenotype. A recent study has identified thrombocytopenia (with a platelet count <30 000 μL)
and hypofibrinogenemia (<0.6 g/L) as independent risk factors for bleeding in acutely ill patients with cirrhosis. 21 It is, however, unknown whether there is a causal link between bleeding risk and these laboratory abnormalities, and studies assessing whether reversal of thrombocytopenia and/or hypofibrinogenemia decrease the bleeding risk in these patients will be required to ascertain this.
It is unknown whether acutely ill patients with cirrhosis are at risk for development of venous thrombosis similar to the increased risk in well compensated patients. 22 Nevertheless, prophylactic or therapeutic antithrombotic strategies may be required in acutely ill patients with cirrhosis, in the context of venous thrombosis, portal vein thrombosis, and thrombosis of extracorporeal assist devices. 15, 23 We have recently studied the haemostatic status of patients with acutely decompensated or acute-on-chronic liver failure and found a remarkably preserved haemostatic system. 24 The relatively wellpreserved haemostatic balance therefore suggests that a defensive prohaemostatic and a proactive antihaemostatic approach may be warranted in these patients.
Given the major alterations in the haemostatic system of patients with cirrhosis, the efficacy of pro-and antihaemostatic strategies may be unpredictable. We have previously demonstrated that in patients with compensated cirrhosis the in vitro anticoagulant effects of some of the commonly used drugs was decreased, whereas the anticoagulant effects of others were increased as compared to anticoagulant effects in healthy individuals. 25, 26 Another study has shown a lack of prohaemostatic effect of in vitro addition of fresh frozen plasma to plasma from patients with compensated cirrhosis, despite improvements in plasma levels of coagulation factors. 27 Similarly, transfusion of platelets to patients with cirrhosis did increase the platelet count, but did not improve global haemostasis. 28 With the aim to provide a more rational approach to pro-and antihaemostatic treatment of acutely ill patients with cirrhosis, and to facilitate design of future clinical studies, we tested the in vitro effects of commonly used pro-and antihaemostatic strategies in plasma from patients with acutely decompensated cirrhosis and acute-on-chronic liver failure.
| MATERIAL S AND ME THODS

| Patients
The 24 In short, patients were sampled on admission and patients were only excluded when currently using antihaemostatic agents.
From the published cohort we studied 30 healthy volunteers, 18 patients with acute decompensation (AD) of cirrhosis and 10 patients with acute-on-chronic liver failure (ACLF). Eighteen patients with well compensated cirrhosis were newly recruited in the outpatient clinic, and were not using antihaemostatic drugs at the time of sampling.
Acute decompensation of chronic liver disease and ACLF were defined and graded according to number of organ failures in concordance with criteria reported in the CANONIC study. 29 From the 10 patients with ACLF, 1 was classified as grade 1 and 9 were grade 3.
| Routine laboratory tests
Haemoglobin, white blood cell count, albumin, creatinine, bilirubin, aspartate transaminase, alanine transaminase and gamma-glutamyl
Key points
• Bleeding and thrombotic events are common in patients with liver disease, but there is uncertainty on optimal management strategies 
| In vitro addition of pro-and anticoagulants
We added the following agents to plasma samples of each patient and control:
• chosen to represent clinically relevant plasmas levels and were identical to levels used in previously published experiments. 25 Importantly, drug concentrations which gave appreciable (but not maximal) inhibition of thrombin generation in pooled normal plasma were selected so it would be possible to detect both increased and decreased drug effects in patients compared to controls.
| Thrombin generation
The thrombin generation test was performed using platelet-poor plasma with the fluorimetric method described by Hemker, 30 Calibrated Automated Thrombography ® in absence or presence of the above-mentioned agents, except for fibrinogen concentrate.
Coagulation was activated using commercially available reagents The pro-or anticoagulant potency of the different agents was expressed as the percentual change in endogenous thrombin potential (ETP), lag time, peak or velocity index after addition of the study agent. These percentages were compared between patients and controls.
| Fibrin concentration and fibrin permeability
Fibrinogen levels in plasma of patients and healthy volunteers were determined on an ACL TOP 300 analyzer using reagents from Instrumentation Laboratory (Breda, the Netherlands) according to the manufacturer's instructions.
The average pore size of the fibrin clot (expressed as the Darcy constant, Ks) was determined in permeation studies as previously described. 11 In short, plasma samples (100 μL) were incubated with 
, and P = pressure drop (dyne/cm). 
| Statistical analyses
| RE SULTS
We studied the effects of ex vivo addition of commonly used pro-and anticoagulant drugs in patients with compensated and decompensated cirrhosis, and in patients with acute-on-chronic liver failure and compared results with those obtained in healthy controls. Table 1 summarises baseline characteristics of patients and controls.
Without the addition of pro-or anticoagulant agents, patients generated more thrombin as compared to controls, using TMmodified thrombin generation tests, which is in line with our previously published data (Table 2) .
When recombinant factor VIIa (50 nmol/L) was added to plasma of healthy individuals, an increase of ~20% in ETP, peak, and velocity index was observed, with an ~20% decrease in lag time. In patients, however, addition of recombinant factor VIIa did not appreciably change ETP, peak, and velocity index, whereas the lag time was
shortened to a similar extent as in controls (Table 3 , Figure 1 The permeability of clots generated from plasma from healthy controls was remarkably similar to that of the permeability of clots from patients, despite the lower fibrinogen levels in patient plasma.
When fibrinogen concentrate (1 g/L) was added to control samples, a 51% reduction in permeability was observed. A similar effect of fibrinogen concentrate was observed in patients compensated cirrhosis, whereas a slightly more robust effect was observed in plasma from AD and ACLF patients with a 61% reduction in permeability in the AD group and a 63% reduction in the ACLF group (Table 4) . (Table 5 , Figure 2 ). However, given the higher baseline ETP in patients, the ETP in the presence of LMWH were similar between patients and controls.
TA B L E 1 Patient characteristics
Controls
| D ISCUSS I ON
Here we have studied the in vitro effects of commonly used pro-and anticoagulant strategies in compensated and acutely ill patients with cirrhosis in comparison to healthy individuals and found remarkable for a number of agents tested, and suggests some agents to be clinically ineffective in these patients. Specifically, the lack of a procoagulant effect of recombinant factor VIIa in patients, and the minimal effect of FFP in the AD group are in line with the lack of evidence supporting the use of recombinant factor VIIa in patients with liver diseases, [31] [32] [33] and with the doubts on the use of FFP in patients with liver disease in general. 34 Our data suggest a procoagulant approach with PCCs and or fibrinogen concentrate to substantially improve haemostatic status in acutely ill patients with liver disease given the profound procoagulant effects of PCC in thrombin generation tests and the improvement of fibrin clot structure by fibrinogen concentrate. This strategy has been reported to be effective in managing bleeding during liver transplantation. 35 However, based on our data, dosing of PCCs should be performed conservatively in acutely ill patients with cirrhosis given the profoundly exaggerated procoagulant response in patients compared to controls. Similarly, our data suggest that substantial dose-adjustments may be required when low molecular weight heparin or direct oral anticoagulants are considered for prophylaxis or treatment of thrombotic complications in acutely ill patients with cirrhosis.
The lack of a procoagulant effect of recombinant factor VIIa in patients with cirrhosis suggests competent tissue factormediated activation of coagulation in these patients, and is also in line with a very modest increase in thrombin generation following administration of recombinant factor VIIa to healthy volunteers. 36 However, as recombinant factor VIIa also has important tissue factor-independent procoagulant activity, 37 it cannot be presumed that this drug does not have some prohaemostatic effect in acutely ill patients with cirrhosis in vivo. It has been previously demonstrated that FFP has no appreciable effects on in vitro thrombin generation in plasma from patients with compensated cirrhosis, despite clear changes in plasma levels of coagulation factors and a decrease in the INR. 27 Here we demonstrate showing that fibrinogen concentrate normalizes fibrin clot permeability in samples taken from patients during liver transplantation. 38 The increased anticoagulant potency of LMWH and profoundly increased anticoagulant potency of dabigatran are in line with previous studies in patients with compensated cirrhosis, 25, 39 and suggest a requirement for conservative dosing particularly of dabigatran in acutely ill patients with cirrhosis. Importantly, although it remains to be established whether dose-adjustments and/or monitoring of drug levels improves the anticoagulant management of acutely ill patients with cirrhosis, monitoring of LMWH by anti-Xa testing is unreliable in patients with cirrhosis. 40 Thrombin generation tests are currently not ready for clinical use, but the development of whole blood generation tests may result in a point-of-care thrombin generation test which may be suitable for anticoagulant monitoring, 41 which might be used to monitor anticoagulant treatment in these difficult patients. Rivaroxaban appears less effective in patients compared to controls which is in line with studies in patients with compensated cirrhosis, 25 and dose increases may be required. However, importantly, although rivaroxaban is less effective in patients as assessed by total thrombin generation, it appears more effective compared to controls in prolonging the lag time of thrombin generation which was also observed in our previous study in compensated cirrhosis. 25 Taken together, our results suggest a profound difference in clinical efficacy of some of the commonly used pro-and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Dose adjustments of some of these agents may be required, either to improve efficacy or to decrease the risk of side effects. Although our studies have been performed using in vitro, plasma-based systems, which do not take the role of blood cells in haemostasis into account, these results may still be clinically relevant. We propose that our study is the starting point for future preclinical and clinical studies that will further explore the need for alternative dosing of pro-and anticoagulants in patients with cirrhosis. Our data may assist in development of urgently needed clinical studies to assess safety and efficacy of strategies to prevent or treat bleeding and thrombotic complications in these complex patients.
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